

RECEIVED

APR 09 2002

1645

TECH CENTER 1600PT3SB21 (08-00)

Approved for use through 10/31/2002, GMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/927,121
		Filing Date	08/10/2001
		First Named Inventor	Gold
		Group Art Unit	1645
		Examiner Name	TBA
Total Number of Pages in This Submission	13	Attorney Docket Number	032077.0003.UTL1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Retn. postcd; copies of 132 cited refs.
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Jeffrey W. Guise, Reg. No.: 34,613
Signature	
Date	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

04-03-02

Typed or printed name	WENDY THERRIEN		
Signature		Date	4/3/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:)
Gold, et al.) Group Art Unit: 1645
Serial No.: 09/927,121) Examiner: TBA
Filed: August 10, 2001)
For: METHOD AND COMPOSITION)
FOR ALTERING A B-CELL MEDIATED)
PATHOLOGY)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The items are listed on the attached Form PTO/SB/08A and copies are enclosed for the convenience of the Examiner. Applicants respectfully request that the documents be made of record in the above-referenced application.

The items identified in this Information Disclosure Statement may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

WENDY THERRIEN
Name of Person Mailing Paper

Wendy Therrien
Signature of Person Mailing Paper

04/03/02
Date of Deposit

admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Information Disclosure Statement is believed to be timely in that it is being submitted under 37 CFR 1.97(b) (3) before the mailing of a first Office Action on the merits, whereby no fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is authorized to charge any required fee to counsel's Deposit Account No. **50-1273**.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 3/29/02

By: 
Jeffrey W. Guise
Reg. No. 34,613

BROBECK, PHLEGER & HARRISON LLP
12390 El Camino Real
San Diego, CA 92130-2081
Phone (858) 720-2500
Fax (858) 720-2555

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

APR 09 2002 06

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

11

Application Number

09/927,121

Filing Date

August 10, 2001

First Named Inventor

Gold

Group Art Unit

TBA

Examiner Name

TBA

Attorney Docket Number

032077.0003.UTL1

TECH CENTER 1600/2000

APR 19 2002

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	3,969,287		Boehringer Mannheim GmbH	7/13/1976	
	AB	4,195,128		Bayer Aktiengesellschaft	3/25/1980	
	AC	4,229,537		New York University	10/21/1980	
	AD	4,247,642		Sumitomo Chem. Co.	1/27/1981	
	AE	4,330,440		Development Finance Corp. of New Zealand	5/18/1982	
	AF	4,661,586		The Board of Trustees of the Leland Stanford Junior University	4/28/1987	
	AG	4,745,051		The Texas A&M University System	5/17/1988	
	AH	4,816,397		Celltech Limited	3/28/1989	
	AI	5,053,224		Koprowski et al.	10/1/1991	
	AJ	5,122,464		Celltech Limited; The University Court of the Univ. of Glasgow	6/16/1992	
	AK	5,227,159		Richard-A. Miller	7/13/1993	
	AL	5,281,699		Tanox Biosystems, Inc.	1/25/1994	
	AM	5,612,035		The Immune Response Corporation	3/18/1997	
	AN	5,650,150		Stephen D. Gillies	7/22/1997	
	AO	5,789,206		Myriad Genetics, Inc.	8/4/1998	
	AP	5,792,445		Bracco International B.V.	8/11/1998	
	AQ	5,861,164		The Immune Response Corp.	1/19/1999	
	AR	5,972,334		Genitope Corp.	10/26/1999	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

APR 03 2002

JCSB

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

CENTER 1600/2001

RECEIVED

U.S. PATENT DOCUMENTS

	AS	6,099,846		The Board of Trustees of the Leland Stanford Junior University	8/8/2000	
--	----	-----------	--	--	----------	--

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
AT	EP	0874054		A2		3/4/98		
AU	JP	10-295379				11/10/98		
AV	WO	00/06733		A2	Heska Corp.	2/10/2000		
AW	WO	00/47228			The Scripps Research Institute	8/17/2000		
AX	WO	92/08495			Abbott Biotech, Inc.	5/29/1992		
AY	WO	97/29769			Biomira USA Inc.	8/21/1997		
AZ	WO	97/35008			The Gov't. of the U.S.A., rep. by The Dept. of Health & Human Services	9/25/1997		
BA	WO	98/30577		A1	Board of Regents, The Univ. of Texas System	7/16/1998		
BB	WO	99/29732			Lexigen Pharm. Corp.	6/17/1999		
BC	WO	99/46392			The Gov't. of the U.S.A., rep. by The Dept. of Health & Human Services	9/16/1999		
BD	WO	99/52562			Lexigen Pharm. Corp.	10/21/1999		
BE	WO	99/57981			Sloan-Kettering Institute for Cancer Research	11/18/1999		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

APR 03 2002

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

RECEIVED
APR 03 2002
U.S. Patent and Trademark Office
Washington, DC 20231

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BF	ARDEN, et al., "Human T-Cell Receptor Variable Gene Segment Families," <u>Immunogenetics</u> , 42:455-500 (1995)	
	BG	BENDANDI, et al., "Complete Molecular Remissions Induced by Patient-specific Vaccination Plus Granulocyte-monocyte Colony-stimulating Factor Against Lymphoma," <u>Nature Medicine</u> , 5:1171-1177 (1999)	
	BH	BERINSTEIN, et al., "Idiotypic Variation in a Human B Lymphoma Cell Line," <u>The Journal of Immunology</u> , Vol. 144, No. 2: 752-758 (1990)	
	BI	BROWN, et al., "Antiidiotype Antibody Therapy of B-Cell Lymphoma," <u>Seminars in Oncology</u> , 16:199-210 (1989)	
	BJ	BROWN, et al., "The Prognostic Significance of Immunophenotype in High-grade Non-Hodgkin's Lymphoma," <u>Histopathology</u> , Vol. 14: 621-627 (1989)	
	BK	BROWN, et al., "Treatment of B-Cell Lymphomas with Anti-idiotype Antibodies Alone and in Combination with Alpha Interferon," <u>Blood</u> , 73(3):651-661 (1989)	
	BL	CAMPBELL, et al., "Idiotype Vaccination Against Murine B Cell Lymphoma, Humoral and Cellular Requirements for the Full Expression of Antitumor Immunity," <u>The Journal of Immunology</u> , 145:1029-1036 (1990)	
	BM	CAMPBELL, et al., "Immunotherapy of Established Murine B Cell Lymphoma, Combination of Idiotype Immunization and Cyclophosphamide," <u>The Journal of Immunology</u> , 141:3227-3233 (1988)	
	BN	CARAYANNOPOULOS, et al., "Recombinant Human IgA Expressed in Insect Cells," <u>Proc. Natl. Acad. Sci.</u> , Vol. 91: 8348-8352 (1994)	
	BO	CASARES, et al., "Antigen-specific Downregulation of T Cells by Doxorubicin Delivered through a Recombinant MHC II-peptide Chimera," <u>Nature Biotechnology</u> , 19:142-147 (2001)	
	BP	CASPAR, et al., "Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formations," <u>Blood</u> , Vol. 90, No. 9, pp. 3699-3706 (November 11, 1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

TECH CENTER 1600/2900

APR 09 2002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BQ	CATON, et al., "Influenza Virus Hemagglutinin-specific Antibodies Isolated from a Combinatorial Expression Library are closely related to the Immune Response of the Donor," <u>Proc. Natl. Acad. Sci.</u> , Vol. 88: 6450-6454 (1990)	
	BR	CHEN and LEVY, "Induction of Autoantibody Responses to GM-CSF by Hyperimmunization with an Id-GM-CSF Fusion Protein, " <u>The Journal of Immunology</u> , 154, pp. 3105-3117 (1995)	
	BS	CHEN, et al., "Idiotype-Cytokine Fusion Proteins as Cancer Vaccines, Relative Efficacy of IL-2, IL-4, and Granulocyte-Macrophage Colony-Stimulating Factor," <u>The Journal of Immunology</u> , 153:4775-4787 (1994)	
	BT	CHESON, et al., "Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas," <u>J. Clin. Oncol.</u> , 17(4):1244 (1999)	
	BU	CHUNDURU, "Exploitation of the Vβ8.2 T Cell Receptor in Protection against Experimental Autoimmune Encephalomyelitis Using a Live Vaccinia Virus Vector," <u>J. Immunol.</u> , 156:4940-45, (1996)	
	BV	CHUNG, et al., "Functional three-domain single-chain T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 91:12654-12658 (1994)	
	BW	CLARK, et al., "Comparison of Human and Mouse T-Cell Receptor Variable Gene Segment Subfamilies," <u>Immunogenetics</u> , 42:531-540 (1995)	
	BX	CLEARY, et al., "Clustering of Extensive Somatic Mutations in the Variable Region of an Immunoglobulin Heavy Chain Gene from a Human B Cell Lymphoma," <u>Cell Press</u> , Vol. 44: 97-106 (1986)	
	BY	DALEY, et al., "Idiotype-Specific Transplantation Resistance to MOPC-315: Abrogation by Post-Immunization Thymectomy," <u>The Journal of Immunology</u> , vol. 120, No. 5 (1978)	
	BZ	DOENECKE, et al., "Rapid Amplification of cDNA ends (RACE) Improves the PCR-based Isolation of Immunoglobulin Variable Region Genes from Murine and Human Lymphoma Cells and Cell Lines," <u>BTS Leukemia</u> , 11:1787-1792 (1997)	
	CA	DRANOFF, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," <u>Proc. Natl. Acad. Sci. USA</u> , 90(8):3539-3543 (1993)	
	CB	EILAT, et al., "Secretion of a soluble, chimeric γδ T-cell receptor – immunoglobulin heterodimer," <u>Proc. Natl. Acad. Sci. USA</u> , 89:6871-6875 (1992)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
CC	•	ENGEL, et al., "High-Efficiency Expression and Solubilization of Functional T Cell Antigen Receptor Heterodimers," <u>Science</u> , 256:1318-1321 (1992)	
CD	•	GEORGE, et al., "Idiotypic Vaccination as a Treatment for a B Cell Lymphoma," <u>The Journal of Immunology</u> , Vol. 141: 2168-2174 (1988)	
CE	•	GILLIES, et al., "Biological Activity and in Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235 (1993)	
CF	•	GOLD, Daniel P., "TCR V Gene Usage in Autoimmunity," <u>Current Opinion in Immunology</u> , 6:907-912 (1994)	
CG	•	GOLD, et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease," <u>Critical Reviews Immunol.</u> , 17:507-10 (1997)	
CH	•	GRABSTEIN, et al., "Induction of Macrophage Tumoricidal Activity by Granulocyte-Macrophage Colony-Stimulating Factor," <u>Science</u> , Vol. 232:506-508 (1986)	
CI	•	GREENBERG, Philip D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," <u>Advances in Immunology</u> , 49:281-355 (1991)	
CJ	•	GREGOIRE, et al., "Engineered secreted T-cell receptor αβ heterodimers," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 88, pp. 8077-8081 (September 1991)	
CK	•	HASEMANN, et al., "High-level Production of a Functional Immunoglobulin Heterodimer in a Baculovirus Expression System," <u>Proc. Natl. Acad. Sci.</u> , 87:3942-3946 (1990)	
CL	•	HASEMANN, et al., "Mutational Analysis of Arsonate Binding by a CRI _{A+} Antibody, V _H and V _L Junctional Diversity are Essential for Binding Activity," <u>The Journal of Biological Chemistry</u> , 266:7626-7632 (1991)	
CM	•	HASEMANN, et al., "Mutational Analysis of the Cross-Reactive Idiotype of the A Strain Mouse," <u>The Journal of Immunology</u> , 147:3170-3179 (1991)	
CN	•	HEUFLER, et al., "Granulocyte/Macrophage Colony-Stimulating Factor and Interleukin 1 Mediate the Maturation of Murine Epidermal Langerhans Cells into Potent Immunostimulatory Dendritic Cells," <u>J. Exp. Med.</u> , 167(2):700-05 (1988)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

APR 08 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
CO	•	HINUMA, et al., "A Novel Strategy for Converting Recombinant Viral Protein into High Immunogenic Antigen," <u>Federation of European Biochemical Societies</u> , 288:138-142 (1991)	
CP	•	HSU, et al., "Tumor-Specific Idiotype Vaccines in the Treatment of Patients with B-Cell Lymphoma – Long-Term Results of a Clinical Trial," <u>Blood</u> , Vol. 89, No. 9, pp. 3129-35 (May 1, 1997)	
CQ	•	HSU, et al., "Vaccination of Patients with B-cell Lymphoma Using Autologous Antigen-pulsed Dendritic Cells," <u>Nature Medicine</u> , 2:52-58 (1996)	
CR	•	HUSE, et al., "General of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246(4935):1275-1281 (1989)	
CS	•	JIANG, et al., "Murine CD8+ Cells that Specifically Delete Autologous CD4+ T Cells Expressing Vb8 TCR: A Role of the Qa-1 Molecule," <u>Immunity</u> , 2:185-94 (1995)	
CT	•	KAPPLER, et al., "Binding of a soluble αβ T-cell receptor to superantigen/major histocompatibility complex ligands," <u>Proc. Natl. Acad. Sci. USA</u> , 91:8462-8466 (1994)	/
CU	•	KUMAR, et al., "Recombinant T Cell Receptor Molecules Can Prevent and Reverse Experimental Autoimmune Encephalomyelitis," <u>J. Immunol.</u> , 159:5150-5156 (1997)	
CV	•	KURUCZ, et al., "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 90:3830-3834 (1993)	
CW	•	KWAK, et al., "Combined Syngenic Bone Marrow Transplantation and Immunotherapy of a Murine B-Cell Lymphoma: Active Immunization with Tumor-Derived Idiotypic Immunoglobulin," <u>Blood</u> , 76(11):2411-2417 (1990)	
CX	•	KWAK, et al., "Idiotypic Vaccination as Therapy for Multiple Myeloma," <u>Seminars in Hematology</u> , 36:34-37 (1999)	
CY	•	KWAK, et al., "Introduction of Immune Responses in Patients with B-Cell Lymphoma Against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors," <u>N. Eng. J. Med.</u> , 327:1209-1215 (1992)	
CZ	•	KWAK, et al., "Transfer of Myeloma Idiotype-specific Immunity from an Actively Immunised Marrow Donor," <u>The Lancet</u> , 345:1016-1020 (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

O I P E
APR 08 2002
JC58

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	DA *	KWAK, et al., "Vaccination with Syngeneic, Lymphoma-derived Immunoglobulin Idiotype Combined with Granulocyte/Macrophage colony-stimulating Factor Primes Mice for a Protective T-cell Response," <u>Proc. Natl. Acad. Sci.</u> , 93:10972-10977 (1996)	
	DB *	LEBOWITZ, et al., "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: Biochemical Probes for Analysis and Modulation of Immune Responses," <u>Cell. Immun.</u> , 192:175-184 (1999)	
	DC *	LEVITISKY, et al., "Immunization with Granulocyte-Macrophage Colony-Stimulating Factor-Trasduced, but Not B7-1-Transduced, Lymphoma Cells Primes Idiotype-Specific T Cells and Generates Potent Systemic Antitumor Immunity," <u>J. Immunol.</u> , 156 (10):3858-3865 (1996)	
	DD *	LEVY, et al., .., "Mutational Hot Spots in Ig V Region Genes of Human Follicular Lymphomas," <u>J. Exp. Med.</u> , 168(2):475-489 (1988)	
	DE *	LIN, et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form," <u>Science</u> , 249:677-679 (1990)	
	DF *	MAECKER and LEVY, "Spontaneous T Cell Antigen Receptor Variants of a Human T Leukemia Cell Line," <u>J. Immunol.</u> , 141:2994-3002, (1985)	
	DG *	MALKOVSKA, et al., "Human T Cells in hu-PBL-SCID Mice Proliferate in Response to Daudi Luymphoma and Confer anti-tumour Immunity," <u>Clin. Exp. Immunol.</u> , 96:158-165 (1994)	
	DH *	MALONEY, et al., "Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere With the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells," <u>Blood</u> , 80(6):1502-1510 (1992)	
	DI *	MASSAIA, et al., "Idiotype Vaccination in Human Mycloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy," <u>Blood</u> , 94:673-683 (1999)	
	DJ *	MCKEEVER, et al., "Immunization with Soluble BDC 2.5 T Cell Receptor-Immunoglobulin Chimeric Protein: Antibody Specificity and Protection of Nonobese Diabetic Mice against Adoptive Transfer of Diabetes by Maternal Immunization," <u>J. Exp. Med.</u> , 184:1755-1768 (1996)	
	DK *	MEEKER, et al., "A Clinical Trial of Anti-Idiotype Therapy for B Cell Malignancy," <u>Blood</u> , 65:1349-1363 (1985)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

APR 08 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	DL ✓	MEEKER, et al., "Emergence of Idiotype Variants During Treatment of B-Cell Lymphoma with Anti-Idiotype Antibodies," <u>N. Eng. J. Med.</u> , 312:1658-1665 (1985)	
	DM ✓	MILLER, et al., "Treatment of B-Cell Lymphoma with Monoclonal Anti-idiotype Antibody," <u>N. Eng. J. Med.</u> , 306(9):517-522 (1982)	
	DN ✓	MINTY, et al., "Molecular Cloning of the MCP-3 Chemokine Gene and Regulation of its Expression," <u>Eur. Cytokine Netw.</u> , 4(2):99-110 (1993)	
	DO *	MORRISSEY, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments the Primary Antibody Response by Enhancing the Function of Antigen-Presenting Cells," <u>J. Immunol.</u> , 139(4):1113-1119 (1987)	
	DP ~	MROCKOWSKI, et al., "Secretion of Thermostable DNA Polymerase Using a Novel Baculovirus Vector," <u>J. Biol Chem.</u> , 269:13522-13528 (1994)	
	DQ ●	MULLINAX, et al., "Identification of Human Antibody Fragment Clones Specific for Tetanus Toxoid in a Bacteriophage A Immunoexpression Library," <u>Proc. Natl. Acad. Sci. USA</u> , 87(20):8095-8099 (1990)	
	DR *	NELSON, et al., "Tumor-Specific, Cytotoxic T-Lymphocyte Response After Idiotype Vaccination for B-Cell, Non-Hodgkin's Lymphoma," <u>Blood</u> , 88:580-589 (1996)	
	DS ●	NESBIT, et al., "Production of a Functional Monoclonal Antibody Recognizing Human Colorectal Carcinoma Cells from a Baculovirus Expression System," <u>Immunol. Methods</u> , 151:201:208 (1992)	
	DT *	NOVOTNY, et al., "A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8646-8650 (1991)	
	DU ●	O'HERRIN, et al., "Analysis of the Expression of Peptide - Major Histocompatibility Complexes Using High Affinity Soluble Divalent T Cell Receptors," <u>J. Exp. Med.</u> , 186(8):1333-1345 (1997)	
	DV *	ODENDAHL, et al., "Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus," <u>J. Immunol.</u> , 165(10):5970-5979 (2000)	
	DW *	OFFNER, et al., "Vaccination with BV8S2 Protein Amplifies TCR-Specific Regulation and Protection Against Experimental Autoimmune Encephalomyelitis in TCR BV8S2 Transgenic Mice," <u>J. Immunol.</u> , 161:2178-2186 (1998)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 08 2002

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

9

of

11

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
DX	◦	OGAWA, et al., "Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ Cells in Peripheral Blood Derived from Patients with Autoimmune Hepatitis or Chronic Hepatitis C with Autoimmune Phenomena," <u>J. Gastroenterol. Hepatol.</u> , (1):69-75 (2000)	
DY	◦	OKADA, et al., "TCR Vaccines for Active Immunotherapy of T Cell Malignancies," <u>J. Immunol.</u> , 159:5516-5527 (1997)	
DZ	◦	OPDENAKKER, et al., "Human Monocyte Chemotactic Protein-3 (MCP-3): Molecular Cloning of the cDNA and Comparison with other Chemokines," <u>Biochem. Biophys. Res. Comm.</u> , 191(2):535-542 (1993)	
EA	◦	ORLANDI, et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," <u>Proc. Natl. Acad. Sci. USA</u> , 86(10) 3833-3837 (1989)	
EB	◦	POTTER, et al., "Anti-idiotypic Antibody D12 and Superantigen SPA Both Interact with Human V _H 3-encoded Antibodies on the External Face of the Heavy Chain Involving FR1, CDR2, and FR3," <u>Molecular Immunology</u> , 35:1179-1187 (1998)	
EC	◦	POTTER, et al., "Staphylococcal Protein A Binding to V _H 3 Encoded Immunoglobulins," <u>Intern. Rev. Immunol.</u> , 14:291-308 (1997)	
ED	◦	POTTER, et al., "Staphylococcal Protein A Simultaneously Interacts with Framework Region 1, Complementarity-Determining Region 2, and Framework Region 3 on Human V _H 3-Encoding Ig ^s ," <u>The Journal of Immunology</u> , 157:2982-2988 (1996)	
EE	◦	POTTER, et al., "The Cross-Reactive Idiotypes Recognized by the Monoclonal Antibodies 9G4 and LC1 are Located in Framework Region 1 of Two Non-Overlapping Subsets of Human V _H 4 Family Encoded Antibodies," <u>Scand. J. Immunol.</u> , 40:43-49 (1994)	
EF	◦	PROOST, et al., "Human Monocyte Chemotactic Proteins-2 and -3: Structural and Functional Comparison with MCP-1," <u>J. Leukoc. Biol.</u> , 59(1):67-74 (1996)	
EG	◦	RAUER and KAISER, "Demonstration of Anti-HuD Specific Oligoclonal Bands in the Cerebrospinal Fluid from Patients with Paraneoplastic Neurological Syndromes Qualitative Evidence of Anti-HuD Specific IgG-synthesis in the Central Nervous System," <u>J. Neuroimmunol.</u> , 111(1-2):241-244 (2000)	
EH	◦	ROWEN, et al., "The Complete 685-Kilobase DNA Sequence of the Human β T Cell Receptor Locus," <u>Science</u> , 272:1755-1762 (1996)	
EI	◦	RUBERTI, et al., "The Use of the RACE Method to Close Hybridoma cDNA when V Region Primers Fail," <u>Journal of Immunological Methods</u> , 173:33-39 (1994)	
EJ	◦	SAKATO, et al., "Suppression of MOPC-167 Growth <i>In Vivo</i> by Immunization Against the Idiotype of the MOPC-167 Myeloma Protein," <u>Microbiol. Immunol.</u> , 23:927-931 (1979)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

APR 03 2002

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

10

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
EK	6	SANTOLI, et al., "Amplification of IL-2-Driven T Cell Proliferation by Recombinant Human IL-3 and Granulocyte-Macrophage Colony-Stimulating Factor," <u>J. Immunol.</u> , 141(20):519-526 (1988)	
EL	7	SINCLAIR, et al., "PCR Strategies for Isolation of the 5' End of an Immunoglobulin-encoding Bovine cDNA," <u>Gene</u> , 167:285-289 (1995)	
EM	8	SINGH and O'HAGAN, "Advances in Vaccine Adjuvants," <u>Nature Biotech.</u> , 17:1075-1081 (1999)	
EN	9	SMITH, et al., "Direct Evidence for an Intracellular Role for IFN-γ" Microinjection of Human IFN-γ Induces Ia Expression on Murine Macrophages, <u>J. Immunol.</u> , 144(5):1777-1782 (1990)	
EO	10	STEVENSON and GORDON, "Immunization with Idiotypic Immunoglobulin Protects Against Development of B Lymphocytic Leukemia, But Emerging Tumor Cells can Evade Antibody Attack by Modulation," <u>J. Immunol.</u> , 130(2):970-973 (1983)	
EP	11	TAO and LEVY, "Idiotype/granulocyte-macrophage Colony-stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," <u>Nature</u> , 362(6422):755-758 (1993)	
EQ	12	TESSIER, et al., "Enhanced Secretion from Insect Cells of a Foreign Protein Fused to the Honeybee Melittin Signal Peptide," <u>Gene</u> , 98:177-183 (1991)	
ER	13	VAN HALL, et al., "Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin," <u>J. Immunol.</u> , 165:869-877 (2000)	
ES	14	VAINIENE, et al., "Natural Immunodominant and Experimental Autoimmune Encephalomyelitis-Protective Determinants Within the Lewis Rat Vβ8.2 Sequence Include CDR2 and Framework 3 Idiotopes," <u>Journal of Neuroscience Research</u> , 43:137-145 (1996)	
ET	15	VANDENBARK, et al., "Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops," <u>Critical Reviews Immunol.</u> , 20:57-83 (2000)	
EU	16	WAISMAN, et al., "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity," <u>Nature Med.</u> , 2(8):899-905 (1996)	
EV	17	WARE, et al., "Human CD8+ Lymphocyte Clones Specific for T Cell Receptor VB Families Expressed on Autologous CD4+ T Cells," <u>Immunity</u> , 2:177-184 (1995)	
EW	18	WARREN and CATZ, "Kinetic Profiles of Cerebrospinal Fluid Anti-MBP in Response to Intravenous MBP Synthetic Peptide DENP ₈₅ VVHFFKNIVTP ₉₆ RT in Multiple Sclerosis Patients," <u>Mult. Scler.</u> , 6(5):300-311 (2000)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 08 2002


PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Please type a plus sign (+) inside this box → +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

11

of

11

Complete if Known

Application Number	09/927,121
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA

Attorney Docket Number 032077.0003.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
EX	o	WEBER, et al., "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor," <i>Nature</i> , 356:793-796 (1992)	
EY	-	WILSON, et al., "Results of a phase I clinical trial of T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations," <i>J. Neuroimmunol.</i> , 76:15-28 (1997)	
EZ	-	YOUNG, et al., "Comparison of the Effects of IL-3, Granulocyte-Macrophage Colony-Stimulating Factor, and Macrophage Colony-Stimulating Factor in Supporting Monocyte Differentiation in Culture," <i>J. Immunol.</i> , 145(2):607-615 (1990)	
FA	-	ZHANG, et al., "Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosys," <i>J. Immunol.</i> , 166(1):6-10 (2001)	
FB	-	ZHANG, et al., "Increased Frequency of Interleukin 2-responsive T Cells Specific for Myelin Basic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis," <i>J. Exp. Med.</i> , 179:973-984 (1994)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.